Stock Quote - HSM-T
*Delayed quote courtesy of Google.
Stock Quote - HSDT
*Delayed quote courtesy of Google.
Sitemap
Main Menu
- Home
- About
- Divisions
- Investor Relations
- Stock Info
- Events
- Upcoming Events
- Virtual Summer Summit: Helius Medical Technologies
- Past Events
- LD Micro Conference
- Equities.com Small-Cap Stars Conference
- J.P. Morgan Healthcare Conference
- 27th Annual ROTH Conference
- Canaccord Genuity – Medical Technology & Diagnostics Forum
- JPMorgan Healthcare Conference
- 37th Annual Health Care Conference
- 20th Annual Global Investment Conference Sponsored by Rodman & Renshaw and H.C. Wainwright & Co.
- Helius Medical Technologies, Inc. Fourth Quarter 2018 Earnings Conference Call
- The MicroCap Conference
- Ladenburg Thalmann 2018 Healthcare Conference
- Medical Alley Innovation Summit
- Helius Medical Technologies, Inc. Third Quarter 2018 Earnings Conference Call
- Canaccord Genuity Medical Technologies & Diagnostics Forum
- Oppenheimer’s 29th Annual Healthcare Conference
- Helius Medical Technologies, Inc. First Quarter 2019 Earnings Conference Call
- Helius Medical Technologies to Present at JMP Securities Life Sciences Conference
- Helius Medical Technologies, Inc. Second Quarter 2019 Earnings Conference Call
- Helius Medical Technologies, Inc. Third Quarter 2019 Earnings Conference Call
- Helius Medical Technologies, Inc. First Quarter 2020 Earnings Conference Call
- Code of Conduct
- Criteria for Ethical Decision Making
- Ethical Business Practices
- Fair Dealings
- Corporate Opportunities and Duty of Loyalty
- Conflicts of Interest
- Accepting or Giving Gifts
- Fraud, Theft or Dishonesty
- Compliance with Laws, Regulations and Rules
- Insider Information also known as “Tipping”
- Accounting and Recordkeeping
- Use of Company Property and Resources
- Proprietary and Confidential Information, Intellectual Property and Inventions
- Reporting and Compliance Procedures
- Whistle-blower Protection
- Waivers and Amendments
- Administration and Distribution
- Corporate Documents
- Committee Charters
- SEC Filings
- Financial Information
- Investor FAQ
- On which exchange is Helius Medical Technologies listed and what is the ticker symbol?
- When did Helius Medical Technologies go public?
- Where is Helius Medical Technologies incorporated?
- Where is Helius Medical Technologies headquarters?
- What is Helius Medical Technologies’ fiscal year?
- How can I purchase shares?
- Is there a way to purchase Helius stock directly from the company?
- Do you pay dividends or is there a reinvestment plan?
- How do I obtain a copy of the company's annual report?
- How can I request any additional financial information about Helius Medical Technologies?
- How can I keep up-to-date with latest developments at Helius?
- How can I replace my lost stock certificate?
- If my address changes, whom should I notify?
- Who is the company’s independent registered public accounting firm?
- Which Investor Relations firm does Helius Medical Technologies use?
- Newsroom
- Independent Research Published Show Positive Results on Translingual Neurostimulation Plus Physical Therapy With Statistically Significant Improvement in Balance and Gait Scores and the Outcomes Were Sustained for 12 Weeks After Discontinuing Treatment
- Helius Medical Technologies Awarded Pioneer Technology Development Award
- Helius Medical Technologies, Inc. and University Health Network (UHN) Have Signed an Agreement for UHN and three Neuro-Rehabilitation Centers to Perform a Clinical Experience Program of the PoNS™ Device in Canada
- Helius Medical Technologies, Inc. Issues a Clarification to the News Release Regarding the Agreement with the University Health Network (UHN) Issued at 7:05 am January 16, 2020
- Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2019 Financial Results on March 12, 2020
- Helius Medical Technologies Inc. Welcomes Cline Medical Centre as an Authorized PoNS Treatment™ Clinic in Nanaimo, BC
- Helius Medical Technologies CEO Philippe Deschamps to Deliver Congressional Briefing on the Latest Technologies, Innovations and Policies in Clinical Neuroscience
- Helius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Canada for Multiple Sclerosis (MS) Label Expansion and New US Regulatory Prioritization for MS
- Helius Medical Technologies, Inc. Provides Details on Five Recently Authorized PoNS Treatment™ Clinics
- Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results; Introduces Full Year 2020 Outlook
- Helius Medical Technologies Announces $2.2 Million Registered Direct Offering
- Helius Medical Technologies Announces Authorization from Health Canada to Market the PoNS™ Device for the Treatment of Gait Deficit Due to Mild and Moderate Multiple Sclerosis (MS)
- Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors
- Helius Medical Technologies to Release First Quarter of Fiscal Year 2020 Financial Results on May 7, 2020
- Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI
- UPDATE -- Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI
- Helius Medical Technologies, Inc. Reports First Quarter of Full Year 2020 Financial Results; Updates Full Year 2020 Outlook
- Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis
- Helius Medical Technologies to Present at the Virtual Summer Summit on June 9th
- Helius Medical Technologies Announces the Dismissal of the Shareholder Class Action Lawsuit
- Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020
- 2019
- Helius Medical Technologies, Inc. Announces Third Collaboration to Implement Clinical Experience Programs with PoNS™ Treatment in the United States
- Helius Medical Technologies, Inc. Announces Fourth Partnership to Implement Clinical Experience Programs with PoNS™ Treatment in the United States
- Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS™ Device
- Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2018 Financial Results on March 14, 2019
- Uptick Newswire Hosts Helius Medical Technologies, Inc. on the Stock Day Podcast to Discuss the Company’s Clearance in Canada and Expansion into The United States and Europe
- Helius Medical Technologies, Inc. Announces Company-Hosted Event at Medical Meeting in March
- Helius Medical Technologies, Inc. Announces First Patients in Canada Treated with Commercially Available PoNS™ Treatment
- Helius Medical Technologies, Inc. to Present at Oppenheimer’s 29th Annual Healthcare Conference
- Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Introduces Full Year 2019 Outlook
- Helius Medical Technologies to Release First Quarter of Fiscal Year 2019 Financial Results on May 9, 2019
- Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS™ Device
- Helius Medical Technologies, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook
- Helius Medical Technologies, Inc. Announces Addition of Three New PoNS™ Authorized Clinics in Canada
- Helius Medical Technologies to Present at the JMP Securities Life Sciences Conference
- Helius Medical Technologies, Inc. Announces Scientific Publication Confirming Tongue Stimulation with PoNS™ Alters Brain Activity
- Helius Medical Technologies, Inc. Provides a Business Update on FDA Strategy
- Helius Medical Technologies to Release Second Quarter of Fiscal Year 2019 Financial Results on August 8, 2019
- Helius Medical Technologies, Inc. Announces Results of Matters Submitted for Vote at 2019 Annual Meeting of Stockholders
- Helius Medical Technologies, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook
- Helius Medical Technologies, Inc. Provides a Business Update on Clinical Experience to Date in Canada
- Helius Medical Technologies, Inc. Announces Addition of a New PoNS™ Clinic in Quebec City, Canada
- Helius Medical Technologies to Release Third Quarter of Fiscal Year 2019 Financial Results on November 12, 2019
- Helius Medical Technologies, Inc. Announces Update on US Regulatory Strategy Following Pre-Submission Meeting with FDA
- Helius Medical Technologies, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update; Updates Full Year 2019 Outlook
- Helius Medical Technologies, Inc. Announces Addition of P3 Health As New Authorized PoNS Treatment™ Clinic in Toronto, Canada
- Helius Medical Technologies, Inc. Announces Proposed Public Offering
- Helius Medical Technologies, Inc. Announces Pricing of Public Offering
- Independent Research Published Show Positive Results on Translingual Neurostimulation Plus Physical Therapy With Statistically Significant Improvement in Balance and Gait Scores and the Outcomes Were Sustained for 12 Weeks After Discontinuing Treatment
- 2018
- Helius Medical Technologies Announces Planned Five-for-One Reverse Stock Split
- Helius Medical Technologies Selects Key Tronic Corporation as its Commercial Contract Manufacturing Partner
- Helius Medical Technologies and HealthTech Connex Announce EEG Study Showing Stimulation by the Investigational PoNS® Device Impacts Brain Activity
- Helius Medical Technologies Completes Reverse Split of its Class A Common Stock
- Helius Medical Technologies and US Army Research Laboratory Launch Additional PoNS® Research
- Helius Medical Technologies, Inc. Announces Proposed Public Offering of Class A Common Stock and Warrants
- Helius Medical Technologies, Inc. Announces Uplisting to Nasdaq and Pricing of Public Offering of Class A Common Stock and Warrants
- Helius Medical Technologies, Inc. to Ring the Nasdaq Closing Bell on June 5th
- Helius Medical Technologies, Inc. Provides Update on its Anticipated Submission for FDA Clearance of the PoNS™ Device
- Helius Medical Technologies, Inc. Joins Russell 3000® Index, Russell 2000® Index and Russell Microcap® Index
- Helius Medical Technologies, Inc. Announces MRI Confirmatory Evidence of Neuroplastic Change after Investigational PoNS™ Treatment Presented at the 2018 Joint Annual Meeting ISMRM – ESMRMB in Paris, France
- Helius Medical Technologies, Inc. Names Jennifer Laux as Chief Commercialization Officer
- Helius Medical Technologies, Inc. Announces Results of Matters Submitted for Vote at 2018 Annual Shareholder Meeting
- Helius Medical Technologies Submits Request for FDA 510(k) Clearance of the PoNS™ Device
- Helius Medical Technologies to Participate in the 20th Annual Global Investment Conference Sponsored by Rodman & Renshaw and H.C. Wainwright & Co.
- Helius Announces First Partnership to Implement Clinical Experience Programs With the Investigational PoNS™ Therapy in the United States
- Helius Medical Technologies to Participate in Three Upcoming Conferences in October
- Helius Medical Technologies Submits Medical Device License Application to Health Canada for PoNS™ Device
- Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure
- Helius Medical Technologies to Release Third Quarter 2018 Financial Results on November 8, 2018
- Helius Medical Technologies Receives Medical Device License Clearance from Health Canada for PoNS™ Device
- Helius Medical Technologies, Inc. Announces Second Partnership to Implement Clinical Experience Programs with PoNS™ Treatment in the United States
- Helius Medical Technologies to Present at the 12th Annual Canaccord Medical Technologies & Diagnostics Forum
- Helius Medical Technologies, Inc. Reports Third Quarter 2018 Financial Results
- Helius Medical Technologies, Inc. Announces Proposed Public Offering of Class A Common Stock
- Helius Medical Technologies, Inc. Announces Pricing of Public Offering of Class A Common Stock
- Helius Medical Technologies, Inc. Announces Exercise of Underwriters’ Overallotment Option
- Helius Medical Technologies, Inc. Submits CE Mark Application for PoNS™ Device
- Archive
- 2017
- Helius Medical Technologies announces that its shelf registration filed on Form S-3 with the US Securities and Exchange Commission (SEC) has been made effective
- Helius Medical Technologies Announces Launch of Fifth Site for Pivotal Mild to Moderate Traumatic Brain Injury Clinical Trial
- Helius Medical Technologies Announces Launch of Sixth Site for Pivotal Mild to Moderate Traumatic Brain Injury Clinical Trial
- Helius Medical Technologies Announces Filing of Final MJDS Base Shelf Prospectus
- Helius Medical Technologies Announces Resignation of Director
- Helius Medical Technologies, Inc. Announces Proposed Public Offering of Class A Common Stock
- Helius Medical Technologies Announces Publication of Multiple Sclerosis Pilot Study Results in Multiple Sclerosis Journal: Experimental, Translational and Clinical
- Helius Medical Technologies Inc. Announces CAD$10.8 Million Public Offering of Class A Common Stock
- Helius Medical Technologies Inc. Closes C$12.5 Million Public Offering of Class A Common Stock, Including Full Exercise of Over-Allotment Option
- Helius Medical Technologies Inc. Announces Upcoming Participation and Presentation at the Cowen and Company 37th Annual Healthcare Conference
- Advocates Reveal State of Progress, Need for More Clinical Research During Brain Injury Awareness Month
- Helius Medical Technologies Signs 5-Year Lease for Corporate Headquarters in Newtown, PA
- Helius Medical Technologies Receives Two Medical Method Patents
- Helius Medical Technologies Receives First of Two Human Performance Patents
- Helius Medical Announces Closing of CAD$7.0 Million Private Placement
- Helius Medical Announces Research Conducted at the Tactile Communication and Neurorehabilition Laboratory (TCNL) Using PoNS™Therapy
- Helius Medical Technologies and the United States Army Medical Research and Materiel Command Announce Last Subject Enrolled In TBI Registrational Clinical Trial
- Helius Medical Technologies Announces Newly Constituted Scientific Advisory Board
- Helius Medical Technologies Celebrates Grand Opening Ribbon Cutting Ceremony of New Corporate Facility in Newtown, PA
- Helius Medical Technologies Announces Extension of Collaborative Research and Development Agreement (CRADA) with US Army
- Helius Medical Technologies Appoints Dane C. Andreeff to Board of Directors
- Helius Medical Technologies Highlights Publication of Stroke Study From The Royal Melbourne Hospital in Australia Using Investigational PoNS™ Device
- Helius Medical Technologies to Present at the Canaccord Genuity Medical Technologies and Diagnostics Conference on November 9, 2017
- Helius Medical Technologies to Report Results from Traumatic Brain Injury Clinical Trials
- Helius Medical Technologies Announces Positive Results from its Registrational Clinical Trial for Traumatic Brain Injury (TBI)
- Helius Medical Technologies Provides Clarification on Clinical Trial Results and Confirms Intention to Include Traumatic Brain Injury (TBI) Registrational and Long-Term Treatment Trial Data to Support Application for Clearance by the FDA
- Helius Medical Technologies Announces Closing of First Tranche of Private Placement
- Helius Medical Technologies Announces Closing of Second Tranche of Private Placement
- Helius Medical Technologies Announces Closing of Final Tranche of Private Placement
- 2016
- Helius Medical Technologies Announces Allowances of 10 New Patents
- Helius Medical Technologies Restates and Re-files Historical Financial Statements
- Helius Medical Technologies Restates and Re-files Historical Financial Statements for Non-Cash Reclassification of Warrants
- Helius Medical Developing New Tech for Brain Trauma
- Helius Medical Announces Proceeds of $1.4 Million from Exercise of Warrants
- Helius Medical Technologies Rings the Opening Bell of the Toronto Stock Exchange
- Helius Medical Technologies Announces Results from a Case Series of Subjects with Advanced MS
- Helius Medical Technologies to Present at 93rd Annual ACRM Conference Plenary Session
- Helius Medical Technologies Announces that Registration Statement on Form S-1 has been Declared Effective
- Helius Medical Technologies Appoints Thomas Griffin to Board of Directors and Chairman of the Audit Committee.
- Helius Medical Technologies Opens New Site for Pivotal Mild to Moderate Traumatic Brain Injury Trial at HealthTech Connex in Surrey, British Columbia
- Helius Medical Technologies Announces Publication of Positive Results of Russian Pediatric Cerebral Palsy Pilot Study
- Helius Medical Technologies to Receive ISO 13485 Certificate – Precursor Certification for Regulatory Applications in Europe, Canada and Australia
- November 9, 2016 Helius Key Opinion Leader Conference Call Details
- Brain Injury Advocates Team Up to “Tackle TBI” in New Public Service Announcement
- Helius Medical Technologies and U.S. Army Extend Sole Source Contract for the PoNS Device Testing and Development
- Helius Medical Technologies and HealthTech Connex Announce Preliminary Research Results Supporting Objective Physiologic Improvement in Cognitive Function with Investigational PoNS™ Therapy in Healthy Adults and Expand Combined Research Initiative
- Full Enrollment Reached in Tactile Communication and Neurorehabilitation Laboratory Clinical Trial
- 2015
- U.S. Army, Helius Medical Technologies Modify CRADA To Speed PONS™ Device Development
- Helius Medical Technologies Announces OTCQB Listing
- Helius Medical Technologies Enrolls First Subjects in Multiple Sclerosis Feasibility Study
- Helius Medical Technologies Announces Appointment of Joyce LaViscount as New Director
- Helius Medical Technologies Grants Stock Options
- Helius Medical Technologies to Start Registrational Trial
- Helius Medical Technologies Inventors Granted US Patent No. 9,020,612 “Non-Invasive Neuromodulation (NINM) For Rehabilitation of Brain Function”
- Helius Medical Technologies Announces Closing of CAD $2,208,110 Non-Brokered Private Placement
- Helius Medical Technologies Achieves Full Enrollment in Canadian MS Feasibility Study
- Helius Medical Technologies Amends and Re-files Historical Financial Statements and Material Change Report
- Helius Medical Technologies Announces Clinical Device Readiness for PoNS 4.0
- Helius Medical Technologies Announces Closing of CAD $875,558 Non-Brokered Private Placement
- U.S. Army and Helius Medical Technologies Execute Sole Source Contract for the PoNS™ Device Testing and Development
- Helius Medical Technologies Inventors’ Granted US PATENT NO. 9,072,889 “Systems for Providing Non-Invasive Neurorehabilitation of a Patient”
- Helius Medical Technologies Announces Closing of CAD $330,738 Non-Brokered Private Placement
- Helius Medical Technologies Issues Corporate Update
- U.S. Army and Helius Medical Technologies Announce Launch of Phase 3 Traumatic Brain Injury Clinical Trial
- Helius Medical Technologies Grants Stock Options
- Helius Medical Technologies Inc. and A&B Company Limited Enter Into Strategic Agreement For The Development of PoNS(TM) Therapy in China, Hong Kong, Macao, Taiwan and Singapore.
- Helius Medical Technologies Names Joyce LaViscount as CFO/COO
- Helius Medical Technologies Grants Stock Options
- Helius Medical Technologies Names Dr. Brian Bapty as VP, Strategy and Business Development and Grants Stock Options
- Helius Medical Technologies Announces Positive Clinical Trial Results from its Multiple Sclerosis Pilot Study
- Helius Medical Technologies Announces Receipt of US$ $2.0 mln from Convertible Credit Facility, Issues Shares and Warrants to A&B Co. Ltd. HK
- Helius Medical Technologies Announces Receipt of Remainder of A&B Funding, Changes to Board of Directors, and Extension of CRADA Agreement Through December 2017
- 2014
- Helius Medical Technologies, Inc. Announces Proposed Acquisition of NeuroHabilitation Corp. and Closing of $7,620,000 Private Placement
- Helius Medical Technologies, Inc. Advances Bridge Loan
- Helius Medical Technologies, Inc. Announces Closing of Plan of Merger with NeuroHabilitation Corporation
- Helius Medical Technologies, Inc. Announces Trading on Canadian Securities Exchange (CNSX: HSM)
- Helius Medical Technologies, Inc. Announces Consulting Agreement and Grant of Options
- Helius Medical Technologies, Inc. to Present at Euro Pacific Capital’s 4th Annual Global Investment Conference
- Helius Announces Pilot Studies for PoNS™ University of Wisconsin – Madison to Study Non-Invasive Neurostimulation Device for Brain-Injured Individuals
- Helius Medical Technologies Announces the Receipt of the Prototype Portable Neuromodulation Stimulator Device “PoNS”™ from Ximedica
- Helius Medical Technologies Announces Health Canada Approval to Start Investigational Testing for the PoNS™ Device
- Helius Medical Technologies’ Inventors Granted US Patent No. 8,849,407, “Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function”
- Helius Medical Technologies Appoints Dr. Jonathan Sackier as Chairman of Scientific Advisory Board
- Helius Medical Technologies Appoints Leading Experts to Inaugural Scientific and Medical Advisory Board
- Helius Medical Technologies Announces Appointment of New Director
- Helius Medical Technologies Announces Russian Distribution Agreement for PoNS™ Device
- Helius Medical Technologies Retains the Trout Group LLC to Support Investor Relations in the US
- Helius Medical Technologies Names Dr. Jonathan Sackier, MB ChB, FRCS, FACS, as Chief Medical Officer
- Helius Medical Technologies Grants Stock Options and Adds to Scientific and Medical Advisory Board
- Helius Medical Technologies Investors’ Granted US Patent No. 8,909,345, “Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function”
- 2017
- 2019
- In the News
- Media Resources
- Our Research
- Contact
- Careers
- Registration
- Form Investigator